Premium
Leave nothing behind: Promising results for coronary drug‐coated balloons in clinical practice
Author(s) -
Claessen Bimmer E.,
Dangas George D.
Publication year - 2019
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.28085
Subject(s) - medicine , restenosis , bare metal , stent , paclitaxel , drug eluting stent , drug , coronary artery disease , bare metal stent , revascularization , surgery , cardiology , myocardial infarction , chemotherapy , psychiatry
Key Points 1,025 patients with de novo coronary artery disease (66.9%) or in‐stent restenosis (ISR) (33.1%) underwent treatment with paclitaxel drug‐coated balloons in a multinational single‐arm registry. Bail‐out stenting rate was only 4.8%. One‐year target lesion revascularization was 2.3% for de novo lesions, 2.9% for bare metal stent ISR, and 5.8% for drug‐eluting stent ISR. Short‐term results with coronary drug‐coated balloons are promising. Nonetheless, long‐term data, preferably from randomized trials are necessary to confirm their safety and efficacy.